Abstract

To observe the efficacy of ezetimibe combined with simvastatin with coronary heart disease patients and its effect on retinol binding protein 4, thioredoxin interaction protein and visceral adipose tissue serine protease inhibitor. 120 patients with coronary heart disease admitted in our hospital from May 2019 to May 2020 were divided into the control group and the observation group. Changes in serum retinol binding protein 4, thioredoxin interaction protein and visceral adipose tissue serine protease inhibitor and blood lipids were recorded. Changes in the Seattle angina scale in the observation group, 18 patients were effective and the total effective rate were 93.33 %; 27 patients showed effect in the control group, 21 patients were effective and the total effective rate was 80.00 %; the total effective rate in the observation group was higher than that in the control group, with statistical significance (p<0.05). Compared with those before treatment, visceral adipose tissue serine protease inhibitor and high density lipoprotein cholesterol increased, retinol binding protein 4, thioredoxin interaction protein, triglyceride, total cholesterol and low density lipoprotein cholesterol decreased in the two groups and visceral adipose tissue serine protease inhibitor and high density lipoprotein cholesterol were higher and retinol binding protein 4, thioredoxin interaction protein, triglyceride, total cholesterol and low density lipoprotein cholesterol were lower in the observation group than those in the control group after 3 mo of treatment (p<0.05). The ezetimibe combined with simvastatin can regulate blood lipid, decrease the expression of retinol binding protein 4, thioredoxin interaction protein and visceral adipose tissue serine protease inhibitor in serum and improve the onset of angina pectoris in patients with coronary heart disease.